These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Less is more: the human microdosing concept. Garner RC Drug Discov Today; 2005 Apr; 10(7):449-51. PubMed ID: 15809185 [No Abstract] [Full Text] [Related]
3. Biomarkers and proof of concept. Ferber G Methods Find Exp Clin Pharmacol; 2002; 24 Suppl C():35-40. PubMed ID: 12575486 [TBL] [Abstract][Full Text] [Related]
4. Strategies for success in drug development. Wardell WM Retina; 2005 Dec; 25(8 Suppl):S100-S102. PubMed ID: 16374309 [No Abstract] [Full Text] [Related]
5. Celebrating the SSCI: the drug discovery pathway: challenges and pitfalls. Bennett JC Am J Med Sci; 2003 Dec; 326(6):329-32. PubMed ID: 14671495 [No Abstract] [Full Text] [Related]
6. Optimizing the preclinical/clinical interface: an Informa Life Sciences conference 12-13 December, 2006, London, UK. Cavero I Expert Opin Drug Saf; 2007 Mar; 6(2):217-24. PubMed ID: 17367268 [TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy: the role of chemistry, manufacturing, and controls in pharmaceutical drug development. DiFeo TJ Drug Dev Ind Pharm; 2004 Mar; 30(3):247-57. PubMed ID: 15109024 [No Abstract] [Full Text] [Related]
8. Evaluation of inhibitory drug interactions during drug development: genetic polymorphisms must be considered. Lee LS; Nafziger AN; Bertino JS Clin Pharmacol Ther; 2005 Jul; 78(1):1-6. PubMed ID: 16003286 [No Abstract] [Full Text] [Related]
9. Clinical Biomarkers Forum--Harnessing the Potential of Biomarkers from Translational Research, throughout Clinical Trials. 13-14 September 2007, Prague, Czech Republic. Guergova-Kuras M IDrugs; 2007 Nov; 10(11):782-3. PubMed ID: 17968758 [No Abstract] [Full Text] [Related]
10. Industry Perspective on Biomarker Development and Qualification. Gerlach CV; Derzi M; Ramaiah SK; Vaidya VS Clin Pharmacol Ther; 2018 Jan; 103(1):27-31. PubMed ID: 29143971 [TBL] [Abstract][Full Text] [Related]
11. Strategies in selecting an agent for clinical trials. Peck RW Ann N Y Acad Sci; 1997 Aug; 823():319-27. PubMed ID: 9292060 [No Abstract] [Full Text] [Related]
12. Applications of metabolomics in drug discovery and development. Wishart DS Drugs R D; 2008; 9(5):307-22. PubMed ID: 18721000 [TBL] [Abstract][Full Text] [Related]
13. The ultimate model organism: progress in experimental medicine. Littman BH; Williams SA Nat Rev Drug Discov; 2005 Aug; 4(8):631-8. PubMed ID: 16056389 [TBL] [Abstract][Full Text] [Related]
14. Quantitative image analysis: software systems in drug development trials. Eckstein F; Englmeier KH Drug Discov Today; 2003 Oct; 8(20):922-3. PubMed ID: 14554153 [No Abstract] [Full Text] [Related]
15. Improved early clinical development through human microdosing studies. Wilding IR; Bell JA Drug Discov Today; 2005 Jul; 10(13):890-4. PubMed ID: 15993808 [No Abstract] [Full Text] [Related]
17. The test of public scrutiny. Mallinckrodt CH Pharm Stat; 2006; 5(4):249-52. PubMed ID: 17219626 [No Abstract] [Full Text] [Related]
18. Next-generation vaccines - An IBC Conference. Harnessing innovative technologies and processes to speed up your research, development & production of novel vaccines part 2. Yuan L IDrugs; 2008 Sep; 11(9):633-5. PubMed ID: 18763210 [No Abstract] [Full Text] [Related]
19. Next-generation vaccines - An IBC Conference. Harnessing innovative technologies and processes to speed up your research, development & production of novel vaccines part 1. Yuan L IDrugs; 2008 Sep; 11(9):630-2. PubMed ID: 18763209 [No Abstract] [Full Text] [Related]
20. Medical nanotechnology: shortening clinical trials and regulatory pathways? Ferrari M; Downing G BioDrugs; 2005; 19(4):203-10. PubMed ID: 16128604 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]